Span-America Declares Quarterly Cash Dividend

Marks 106th Consecutive Quarterly Dividend Payment

GREENVILLE, S.C.--(BUSINESS WIRE)-- Span-America Medical Systems, Inc. (NASDAQ: SPAN) announced today that the Board of Directors declared a quarterly cash dividend of $0.16 per share. The dividend is payable June 2, 2016, to shareholders of record on May 17, 2016.

“This quarter’s cash dividend marks Span-America’s 106th consecutive quarter of paying cash dividends,” stated Jim Ferguson, president and chief executive officer of Span-America. “We believe our long and consistent dividend record highlights our Board’s interest in maintaining a regular quarterly cash dividend as a component of our efforts to build long-term value for our shareholders.”

About Span-America Medical Systems, Inc.

Span-America manufactures and markets a comprehensive selection of pressure management products for the medical market, including Geo-Matt®, PressureGuard®, Geo-Mattress®, Custom Care®, Span+Aids®, Isch-Dish®, Risk Manager® and Selan® products. We also supply custom foam and packaging products to the consumer and industrial markets. Through our wholly-owned subsidiary Span Medical Products Canada Inc., we manufacture and market the M.C. Healthcare Products brands of Encore®, Advantage and Rexx beds as well as related in-room furnishing products for the long-term care market. Span-America’s stock is traded on The NASDAQ Global Market under the symbol “SPAN.” For more information, visit www.spanamerica.com and www.mchealthcare.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160502006185/en/

Span-America Medical Systems, Inc.
Jim Ferguson, 864-288-8877, ext. 6912
President and Chief Executive Officer

Source: Span-America Medical Systems, Inc.

You May Also Be Interested In

• Kinetic Technologies Introduces KTS1642Q Automotive Load Switches Designed to Simplify Compliance with ISO 16750-2 and ISO 7637-2 Power Transient Standards
• Namecheap Hosts Complimentary Webinar on AI-Powered WordPress Website Creation
• OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic